- cafead Apr 09, 2020 at 10:52: AM
via It had a glittering £200 million mega-IPO on the London Stock Exchange in 2014, but failure after trial failure blighted its prospects. A battered Circassia Pharmaceuticals, by 2017 reliant on its asthma management device Niox for revenue, turned to fellow UK drugmaker AstraZeneca to infuse some oxygen into its starved pipeline.
article source
article source